A diagnostics executive at a top pharma company discusses their current explorations of MRD and ctDNA monitoring assays. They are most familiar with Natera and Guardant as vendors, and in the future, they expect tumor-agnostic testing will be favored for broader use. They also provided feedback on ArcherDx, C2I and Grail. While they see utility of these technologies most in CRC and lung cancers, they imagine that there is potential for use in other indications such as breast, prostate, and ovarian cancers. This stakeholder mentioned these technologies already support registrational cancer trials for both targeted and immuno-oncology therapies. They believe that clinician education will be key hurdle needed to drive adoption.
PDF deck with summarized feedback from stakeholders
Individual PDFs of call transcripts with stakeholders
This package includes both the PDF deck and transcripts, providing a comprehensive understanding of stakeholders' views. You will receive a summarized report in the form of a PDF deck, as well as the full transcript of the discussions.
Individual call transcript of a single stakeholder discussing their views. This option is ideal for those who are interested in a specific stakeholder's perspective and insights on the topic.